$3.48
2.05%
Nasdaq, Sep 17, 09:30 am EDT.
ISIN
IL0011313900
Symbol
GLMD

Galmed Pharmaceuticals Ltd. Stock price

$3.37
-1.11 24.80% 1M
-1.52 31.13% 6M
-2.63 43.87% YTD
-8.71 72.10% 1Y
-63.83 94.99% 3Y
-4,143.83 99.92% 5Y
-5,288.63 99.94% 10Y
-20,603.03 99.98% 20Y
Nasdaq, Closing price Fri, Sep 18 2026
-0.11 3.16%
ISIN
IL0011313900
Symbol
GLMD
Industry

Is Galmed Pharmaceuticals Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,133 stocks worldwide.

Key metrics

Basic
Market capitalization
$4.0m
Enterprise Value
$-5.4m
Net debt
positive
Cash
$9.4m
Shares outstanding
830.0k
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.7
P/B
0.3
Financial Health
Equity Ratio
84.7%
Return on Equity
-
ROCE
-84.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
-
EBIT
$-11.8m
Net Income
$-11.1m
Free Cash Flow
$-7.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-61.3%
Net Income
-51.3%
Free Cash Flow
-47.1%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-13.5
FCF per Share
$-9.3
Short interest
0.5%
Employees
5
Rev per Employee
-

Galmed Pharmaceuticals Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Galmed Pharmaceuticals Ltd. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Galmed Pharmaceuticals Ltd. forecast:

Hold
50%
Sell
50%

Financial data from Galmed Pharmaceuticals Ltd.

Mar '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.69 3.69
16% 16%
-
- Research and Development Expense 5.60 5.60
88% 88%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -12 -12
61% 61%
-
Net Profit -11 -11
51% 51%
-

In millions USD.

Don't miss a Thing! We will send you all news about Galmed Pharmaceuticals Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Galmed Pharmaceuticals Ltd. Stock News

Neutral
PRNewsWire
12 days ago
Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. (Yorkville) will be terminated effective immediately The Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and will continue to be listed and traded on the Nasdaq Capital Market under the new ticker symbol RAMAT-GAN, Israel, Sept.
Neutral
PRNewsWire
about one month ago
The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in Israel. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of colon tissue quality.
Neutral
PRNewsWire
about one month ago
Xtandi® (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic prostate cancer (nmCSPC) at high risk of metastasis and for the treatment of patients with metastatic prostate cancer (mCSPC) who are maintaining treatment with a GnRH analogue. Global sales for Xtandi® (marketed by Astellas Pharma and Pfizer) reached approximately $8 billion and $6 billion glob...
More Galmed Pharmaceuticals Ltd. News

Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Head office Israel
CEO Mr. Baharaff
Employees 5
Founded 2000
Website www.galmedpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today